Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

This is an open-label, non-randomized, single-center, phase II study to evaluate the efficacy, toxicity and, tolerability of pre-specified dose attenuated chemotherapy regimens in lung cancer patients with comorbidities.

Trial Details

NCT ID
NCT05800587
Phase
PHASE2
Sponsor
Fox Chase Cancer Center
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Carboplatin
  • Pemetrexed
  • Paclitaxel
  • Nab paclitaxel
  • Docetaxel
  • Gemcitabine
Locations (sample)
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362

Key Eligibility Criteria

  • Must have histologically or cytologically confirmed stage IV (AJCC version 8) lung cancer (small cell or non-small cell). Patients with stage III d…
  • Must fit into at least one of the subgroups of patients as defined in section 3.3.
  • Patients must have planned therapy with a regimen that includes at least one cytotoxic agent as listed in Table 1 (e.g. platinum, taxane, anti-meta…
  • Must have measurable disease as per RECIST criteria 1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →